Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1

Journal of Virology

Volumn 72, Issue 12, 1998, Pages 9855-9864

  Spenlehauer, Catherine ^a   Saragosti, Sentob ^b   Fleury, Hervé J A ^c   Kirn, André ^a   Aubertin, Anne Marie ^a   Moog, Christiane ^a  

^a INSERM   (France)

^b BICHAT HOSPITAL   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; VIRUS ANTIBODY;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

EID: 0031744017     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.12.9855-9864.1998     Document Type: Article

References (74)

1. Baier, M., A. Werner, N. Bannert, K. Metzner, and R. Kurth. 1995. HIV suppression by interleukin-16. Nature 378:563.
2. Bates, P. 1996. Chemokine receptors and HIV-1: an attractive pair? Cell 86: 1-3.
3. Beddows, S., S. Louisirirotchanakul, R. Cheingsong-Popov, P. J. Easterbrook, P. Simmonds, and J. Weber. 1998. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies. J. Gen. Virol. 79:77-82.
4. Bou-Habib, D. C., G. Roderiquez, T. Oravecz, P. W. Berman, P. Lusso, and M. A. Norcross. 1994. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from neutralization. J. Virol. 68:6006-6013.
5. Burton, D. R., J. Pyati, R. Koduri, S. J. Sharp, G. B. Thornton, P. W. H. I. Parren, L. S. W. Sawyer, R. M. Hendry, N. Dunlop, P. L. Nara, M. Lamacchia, E. Garratty, E. R. Stiehm, Y. J. Bryson, Y. Cao, J. P. Moore, D. D. Ho, and C. F. Barbas III. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
6. Cao, Y., L. Qin, L. Zhang, J. Safrit, and D. D. Ho. 1995. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332:201-208.
7. Chaix, M.-L., C. Chappey, I. Couillin, W. Rozenbaum, J.-P. Levy, and S. Saragosti. 1993. Diversity of the V3 region of HIV in Paris, France. AIDS 7: 1199-1204.
8. Cocchi, F., A. L. DeVico, A. Garzino-Demo, S. K. Arya, R. C. Gallo, and P. Lusso. 1995. Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 270:1811-1815.
9. Cohen, J. 1993. Jitters jeopardize AIDS vaccine trials. Science 262:6574-6578.
10. Cohen, J. 1996. Likely HIV cofactor found. Science 272:809-810.
11. Conley, A. J., M. K. Gorny, J. A. Kessler, L. J. Boots, M. Ossorio-Castro, S. Koenig, D. W. Lineberg, E. A. Emini, C. Williams, and S. Zolla-Pazner. 1994. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J. Virol. 68: 6994-7000.
12. Doms, R., and S. Peipert. 1997. Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. Virology 235:179-190.
13. D'Souza, M. P., and B. J. Mathieson. 1996. Early phases of HIV type 1 infection. AIDS Res. Hum. Retroviruses 12:1-9.
14. D'Souza, M. P., G. Milman, J. A. Bradac, D. McPhee, C. V. Hanson, R. M. Hendry, and collaborating investigators. 1995. Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies. AIDS 9:867-874.
15. Emini, E. A., W. A. Scleif, J. H. Numberg, A. J. Conley, Y. Eda, S. Tokiyoshi, S. D. Putney, S. Matsushita, K. E. Cobb, C. M. Jett, J. W. Eichberg, and K. K. Murthy. 1992. Prevention of HIV-1 infection in chimpanzees by gp120 V3 monoclonal antibody. Nature 355:728-730.
16. Garrity, R. R., G. Rimmelzwaan, A. Minassian, W.-P. Tsai, G. Lin, J. J. De Jong, J. Goudsmit, and P. L. Nara. 1997. Refocussing neutralizing antibody response by targeted dampening of an immunodominant epitope. J. Immunol. 159:279-289.
17. Golding, H., P. D'Souza, J. Bradac, B. Mathieson, and P. Fast. 1994. Neutralization of HIV-1. AIDS Res. Hum. Retroviruses 10:633-643.
18. Gorny, M. K., J. P. Moore, A. J. Conley, S. Karwowska, J. Sodroski, C. Williams, S. Burda, L. J. Boots, and S. Zolla-Pazner. 1994. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J. Virol. 68:8312-8320.
19. Harrer, T., E. Harrer, S. A. Kalams, T. Elbeik, S. I. Staprans, M. B. Feinberg, Y. Cao, D. D. Ho, T. Yilma, A. M. Caliendo, R. P. Johnson, S. P. Buchbinder, and B. D. Walker. 1996. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable non progressing HIV type 1 infection. AIDS Res. Hum. Retroviruses 12:585-592.
20. Haynes, B. F., G. Pantaleo, and A. S. Fauci. 1996. Toward an understanding of the correlates of protective immunity to HIV infection. Science 271:324-328.
21. Hwang, S. S., T. J. Boyle, H. K. Lyverly, and B. R. Cullen 1991. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253:71-74.
22. Ivanoff, L. A., J. W. Dubay, J. F. Morris, S. J. Roberts, L. Gutshall, E. J. Sternberg, E. Hunter, T. J. Matthews, and S. R. Petteway. 1992. V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity. Virology 187:423-432.
23. Jahaverian, K., A. J. Langlois, G. J. La Rossa, A. T. Profy, D. P. Bolognesi, W. C. Herlihy, S. D. Putney, and T. J. Matthews. 1990. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 250:1590-1593.
24. Jahaverian, K., A. J. Langlois, C. McDanal, K. L. Ross, L. I. Eckler, C. L. Jellis, A. T. Profy, J. R. Rusche, D. P. Bolognesi, S. D. Putney, and T. J. Matthews. 1989. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. Natl. Acad. Sci. USA 86:6768-6772.
25. Karlsson, G. B., F. Gao, J. Robinson, B. Hahn, and J. Sodroski. 1996. Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses. J. Virol. 70:6136-6142.
26. Klasse, P. J., and J. P. Moore. 1996. Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1. J. Virol. 70:3668-3677.
27. Kliks, S. C., T. Shioda, N. L. Haigwood, and J. A. Levy. 1993. V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 90:11518-11522.
28. Korstrikis, L. G., Y. Cao, H. Ngai, J. P. Moore, and D. D. Ho. 1996. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J. Virol. 70:445-458.
29. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
30. LaCasse, R. A., K. E. Follis, T. Moudgil, M. Trahey, J. M. Binley, V. Planelles, S. Zolla-Pazner, and J. H. Numberg. 1998. Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity. J. Virol. 72:2491-2495.
31. Langedijk, J. P. M., G. Zwart, J. Goudsmitt, and R. H. Meloen. 1995. Fine specificity of antibody recognition may predict substitution in the third variable region of gp120 during HIV type 1 infection. AIDS Res. Hum. Retroviruses 10:1153-1162.
32. + cell anti-HIV activity: noncytolytic suppression of virus replication. AIDS Res. Hum. Retroviruses 6:1039-1050.
33. Mascola, J. R., S. W. Snyder, O. S. Weislow, S. M. Belay, R. B. Belshe, D. H. Schwartz, M. L. Clements, R. Dolin, B. S. Graham, G. J. Gorse, M. C. Keefer, M. J. McElrath, M. C. Walker, K. F. Wagner, J. G. McNeil, F. E. McCuthan, and D. S. Burke for the National Institute of Allergy and Infectious Diseases AIDS Evaluation Group. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 173:340-348.
34. Matthews, T. J. 1994. Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res. Hum. Retroviruses 6:631-632.
35. Mazzoli, S., D. Trabattoni, S. Lo Caputo, S. Piconi, C. Ble, F. Meacci, S. Ruzzante, A. Salvi, F. Semplici, R. Longhi, M. L. Fusi, N. Tofani, M. Biasin, M. L. Villa, F. Mazzotta, and M. Clerici. 1997. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals Nat. Med. 3:1250-1257.
36. Merrifield, R. B. 1963. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. •••:2149.
37. Montefiori, D. C., R. G. Collman, T. R. Fouts, J. Ying Zhou, M. Bilska, J. A. Hoxie, J. P. Moore, and D. P. Bolognesi. 1998. Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage. J. Virol. 72: 1886-1893.
38. Moog, C., H. J. A. Fleury, I. Pellegrin, A. Kirn, and A.-M. Aubertin. 1997. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J. Virol. 71:3734-3741.
39. Moog, C., C. Spenlehauer, H. J. A. Fleury, F. Heshmati, S. Saragosti, F. Letourneur, A. Kirn, and A.-M. Aubertin. 1997. Neutralization of primary human immunodeficiency virus type 1 isolates: a study of parameters implicated in neutralization in vitro. AIDS Res. Hum. Retroviruses 13:19-27.
40. Moore, J. P., Y. Cao, D. D. Ho, and R. A. Koup. 1994. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J. Virol. 68:5142-5155.
41. Moore, J. P., Y. Cao, L. Qing, Q. J. Sattentau, J. Pyati, R. Koduri, J. Robinson, C. F. Barbas III, D. Burton, and D. D. Ho. 1995. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69:101-109.
42. Moore, J. P., Y. Cao, J. Leu, L. Quin, B. Korber, and D. D. Ho. 1996. Interand intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 68:1342-1349.
43. Moore, J. P., and D. D. Ho. 1993. Antibodies to discontinuous or conformational sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J. Virol. 67:863-875.
44. Moore, J. P., and D. D. Ho. 1995. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T-cells. AIDS 9:S117-S136.
45. Moore, J. P., Q. J. Sattentau, R. Wyatt, and J. Sodroski. 1994. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J. Virol. 68:469-484.
46. Moore, J. P., A. Trkola, B. Korber, L. J. Boots, J. A. Kessler, F. E. McCutchan, J. Mascola, D. D. Ho, J. Robinson, and A. J. Conley. 1995. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J. Virol. 69:122-130.
47. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Rüker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
48. O'Brien, W. A., S.-H. Mao, Y. Cao, and J. P. Moore. 1994. Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures. J. Virol. 68:5264-5269.
49. Pal, R., A. Garzino-Demo, P. D. Markham, J. Burns, M. Brown, R. C. Gallo, and A. L. DeVico. 1997. Inhibition of HIV-1 infection by the β-chemokine MDC. Science 278:695-698.
50. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herderwijn, J. Desmyter, and E. De Clerck. 1988. Rapid and automated tetrazolium-based colorometric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
51. Pellegrin, I., E. Legrand, D. Neau, P. Bonot, B. Masquelier, J.-L. Pellegrin, J.-M. Ragnaud, N. Bernard, and H. J. A. Fleury. 1996. Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads. J. Acquired Immune Defic. Syndr. 11:438-447.
52. Pilgrim, A. K., G. Pantaleo, O. J. Cohen, L. M. Fink, J. Y. Zhou, J. T. Zhou, D. P. Bolognesi, A. S. Fauci, and D. C. Montefiori. 1997. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long term non progressive infection. J. Infect. Dis. 176:924-932.
53. Rinaldo, C., X.-L. Huang, Z. Fan, M. Ding, L. Beltz, A. Logar, D. Panicali, G. Mazzara, J. Liebmann, M. Cottrill, and P. Gupta. 1995. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1 long-term nonprogressors. J. Virol. 69:5838-5842.
54. Rowland-Jones, S., J. Sutton, K. Ariyoshi, F. Gotch, D. Whitby, A. Sabally, A. Gallimore, T. Corrah, M. Takiguchi, T. Schultz, A. McMichael, and H. Whittle. 1995. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat. Med. 1:59-64.
55. Rusche, J. R., K. Jahaverian, C. McDanal, J. Petro, D. L. Lynn, R. Grimaila, A. Langlois, R. C. Gallo, L. O. Arthur, P. J. Fischinger, D. P. Bolognesi, S. D. Putney, and T. J. Matthews. 1988. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc. Natl. Acad. Sci. USA 85:3198-3202.
56. Scarlatti, G., J. Albert, P. Rossi, V. Hodara, P. Biraghi, L. Muggiasca, and E. M. Fenyö. 1993. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J. Infect. Dis. 168:207-210.
57. Scarlatti, G., T. Leitner, V. Hodara, M. Jansson, A. Karlsson, J. Wahlberg, P. Rossi, M. Uhlén, E. M. Fenyö, and J. Albert. 1996. Interplay of HV-1 phenotype and neutralizing antibody response in pathogenesis of AIDS. Immunol. Lett. 51:23-28.
58. Schonning, K., C. Nielsen, J. Iversen, J. O. Nielsen, and J.-E. S. Hansen. 1995. Neutralizing antibodies in slowly progressing HIV-1 infection. J. Acquired Immune Defic. Syndr. 10:400-407.
59. Schreiber, M., H. Petersen, C. Wachsmuth, H. Müller, F. Hufert, and H. Schmitz. 1994. Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum. J. Virol. 68:3908-3916.
60. Schreiber, M., C. Wachsmuth, H. Müller, C. Hagen, H. Schmitz, and J. Van Lunzen. 1996. Loss of antibody reactivity directed against the V3 domain of certain human immunodeficiency virus type 1 variants during disease progression. J. Gen. Virol. 77:2403-2414.
61. Schreiber, M., C. Wachsmuth, H. Müller, S. Odemuyiwa, H. Schmitz, S. Meyer, B. Meyer, and J. Schneider-Mergener. 1997. The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain. J. Virol. 71:9198-9205.
62. Shan-Lu, L., T. Schacker, L. Musey, D. Shriner, J. M. McElrath, L. Corey, and J. I. Mullins. 1997. Divergent patterns of progression to AIDS after infection from the same source: human immunodeficiency virus type 1 evolution and antiviral responses. J. Virol. 71:4284-4295.
63. Shioda, T., J. A. Levy, and C. Cheng-Meyer. 1992. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell line and macrophage tropism of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 89:9434-9438.
64. Spear, G. T., D. M. Takefman, S. Sharpe, M. Ghassemi, and S. Zolla-Pazner. 1994. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization. Virology 204:609-615.
65. Steimer, K. S., C. J. Scandella, P. V. Skiles, and N. L. Haigwood. 1991. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120. Science 254:105-108.
66. Trkola, A., T. Dragic, J. Arthos, J. M. Binley, W. C. Olson, G. P. Allaway, C. Cheng-Meyer, J. Robinson, P. J. Maddon, and J. P. Moore. 1996. CD4-dependent, antibody-sensitive interactions between HIV-1 and its coreceptor CCR-5. Nature 384:184-187.
67. Trkola, A., T. Ketas, V. N. Kewalramani, F. Endorf, J. M. Binley, H. Katinger, J. Robinson, D. R. Littman, and J. P. Moore. 1998. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is dependent of coreceptor usage. J. Virol. 72:1876-1885.
68. Trkola, A., A. B. Pomales, H. Yuan, B. Korber, P. J. Maddon, G. P. Allaway, H. Katinger, C. F. Barbas III, D. R. Burton, D. D. Ho, and J. P. Moore. 1995. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-immunoglobulin G. J. Virol. 69:6609-6617.
69. Vancott, T. C., F. R. Bethke, D. S. Burke, R. R. Redfield, and D. L. Birx. 1995. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoproteins by candidate AIDS vaccines. J. Immunol. 155:4100-4110.
70. Vancott, T. C., V. R. Polonis, L. D. Loomis, N. L. Michael, P. L. Nara, and D. L. Birx. 1995. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res. Hum. Retroviruses 11:1379-1391.
71. Weber, J., E.-M. Fenyö, S. Beddows, P. Kaleebu, A. Björndal, and the WHO Network for HIV Isolation and Characterization. 1996. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. J. Virol. 70:7827-7832.
72. Wyatt, R., J. P. Moore, M. Accola, E. Desjardin, J. Robinson, and J. Sodroski. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitope induced by receptor binding. J. Virol. 69:5723-5733.
73. MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain. AIDS Res. Hum. Retroviruses 3:245-251.
74. Zwart, G., H. Langedijk, L. Van der Hoek, J.-J. De Jong, T. F. W. Wolfs, C. Ramautarsing, M. Bakker, A. De Ronde, and J. Goudsmit. 1991. Immunodominance and antigenic variation of the principal neutralizing domain of HIV-1. Virology 181:481-489.